**Core tip:** Surgical left atrial appendage occlusion (s-LAAO) is performed during cardiac surgeries in patients with atrial fibrillation. However, evidence to perform routinely during cardiac surgeries is conflicting and contrasting. It is currently given a class IIb recommendation in the professional medical society guidelines. We sought to perform a meta-analysis of all the studies published to date to evaluate the safety and efficacy of s-LAAO.

INTRODUCTION
============

The left atrial appendage (LAA) is considered to be the dominant source of embolism (\> 90%) in patients with non-valvular atrial fibrillation (AF)\[[@B1]\]. Occlusion or resection of the left atrial appendage occlusion (LAAO) remains an important intervention for prevention of recurrent emboli in patients who are at risk of stroke. LAAO provides an opportunity to avoid systemic anticoagulation, thereby minimizing the risk of bleeding.

Surgical LAAO (s-LAAO) usually involves LAA closure while performing other cardiac surgeries. With the increasing prevalence of AF\[[@B2]\], there is a growing interest in the surgical community for s-LAAO. Prior studies assessing the clinical impact of surgical occlusion of the LAA during cardiac surgery have shown contradictory results\[[@B3]-[@B14]\]. Furthermore, there are no large scale randomized controlled trials evaluating routine s-LAAO during cardiac surgery. Therefore s-LAAO remains a class IIb recommendation in professional medical society guidelines\[[@B15],[@B16]\]. Despite this recommendation, s-LAAO is routinely performed in patients with AF undergoing cardiac surgery. Therefore, we sought to perform a meta-analysis of the available studies published to date to evaluate the safety and efficacy of concomitant s-LAAO *vs* no occlusion during cardiac surgery\[[@B3],[@B4],[@B6]-[@B14]\].

MATERIALS AND METHODS
=====================

Search strategy
---------------

The systematic review and meta-analysis was done in compliance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines\[[@B17]\]. The PRISMA checklist is presented in Supplementary Table [1](#T1){ref-type="table"}. The initial search strategy was developed by two authors (V.A and M.A.N). We performed a systematic search, without language restriction, using PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov from inception to May 31st, 2018 for studies comparing s-LAAO *vs* no occlusion- only in patients undergoing concomitant cardiac surgery. We used the following keywords and medical subject heading: "Cardiac surgeries" OR "Heart surgeries" OR "Cardiac surgical procedures" AND "Left atrial appendage" OR "occlusion" OR "ligation" OR "resection" OR "excision" OR "amputation".

###### 

Characteristics of the included studies

  **Study, yr**                           **Country**     **Study period**   **Study design**   **Sample size**   **Cardiac surgery type**   **Follow up period (mo)**   
  --------------------------------------- --------------- ------------------ ------------------ ----------------- -------------------------- --------------------------- -------------
  García-Fernández et al, 2003\[[@B3]\]   Spain           2003               retrospective      58                147                        MVS                         69.4 ± 67
  Healey et al, 2005\[[@B7]\]             Germany         2001-2002          RCT                52                25                         CABG                        13 ± 7
  Nagpal et al, 2009\[[@B8]\]             Canada          2007-2007          RCT                22                21                         MVS                         \<1
  Whitlock et al, 2013\[[@B9]\]           Canada          2009-2010          RCT                26                25                         CABG and VS                 1
  Zapolanski et al, 2013\[[@B4]\]         United States   2005-2012          retrospective      808               969                        CABG and VS                 NR
  Kim et al, 2013\[[@B6]\]                United States   2001-2010          retrospective      631               631                        CABG and MVS                1
  Lee et al, 2014^1\[[@B5]\]^             Korea           1999-2011          retrospective      119               119                        MVS with AF ablation        63 ± 44
  Melduni et al, 2017^1\[[@B10]\]^        United States   2000-2005          prospective        461               461                        CABG and VS                 109.2
  Elbadawi et al, 2017^2\[[@B11]\]^       United States   1998-2013          retrospective      652               652                        VS                          In-hospital
  Elbadawi et al, 2017\[[@B12]\]          United States   2004-2013          retrospective      2519              12595                      CABG                        In-hospital
  Friedman et al, 2018\[[@B14]\]          United States   2011-2012          retrospective      3892              6632                       CABG, MVS, AVS              31.2
  Yao et al, 2018^1\[[@B13]\]^            United States   2009-2017          retrospective      4295              4295                       CABG, VS                    25.2 ± 22.8

RCT: Randomized controlled trial; CABG: Coronary artery bypass grafting; VS: Valvular surgery; MVS: Mitral valve surgery; AVS: Aortic valve surgery; AF: Atrial fibrillation. ^1^Propensity match studies. ^2^Case matching study.

Study selection and data extraction
-----------------------------------

Only studies comparing s-LAAO *vs* no occlusion during any cardiac surgery were included in our analysis. The reference lists of original studies, conference abstracts and relevant review articles were further reviewed. Two investigators (V.A and M.A.N) independently performed the literature search, reviewed the originally identified titles and abstracts and selected studies for pooled analysis based on the inclusion criteria. Any divergence was resolved through discussion with a third independent reviewer (M.K.T). The quality of observational studies was assessed using the Newcastle Ottawa scale, Supplementary Table [2](#T2){ref-type="table"}.

###### 

Baseline and procedural characteristics of included studies

  **Study**                               **Age (mean ± SD)**   **Hypertension**   **AF (%)**   **Technique of s-LAAO**                            
  --------------------------------------- --------------------- ------------------ ------------ ------------------------- ------ ----------------- -----------------------------------
  García-Fernández et al, 2003\[[@B3]\]   63 ± 12               62 ± 10            NR           NR                        NR                       Double suturing
  Healey et al, 2005\[[@B7]\]             72 ± 6                71 ± 5             75           92                        17     8                 Suture or stapler
  Nagpal et al, 2009\[[@B8]\]             57.8 ± 13.3           59.2 ± 11.9        NR           NR                        18     29                Resection
  Whitlock et al, 2013\[[@B9]\]           77.4 ± 6.8            74.6 ± 7.6         92.3         92                        100    100               Amputation and closure or stapler
  Zapolanski et al, 2013\[[@B4]\]         70.52 ± 11.83         83.9               80.6         19.9                      10.7   Double ligation   
  Kim et al, 2013\[[@B6]\]                66.6 ± 11.4           65.8 ± 11.6        80.9         73.1                      NR     NR                Ligation and excision
  Lee et al, 2014\[[@B5]\]                55.9 ± 12.2           50.7 ± 12.4        19.8         14.5                      100    100               Amputation
  Melduni et al, 2017\[[@B10]\]           67.4 ± 12.7           67.6 ± 13.5        59           61                        47     45                Amputation, suturing or stapler
  Elbadawi et al, 2017\[[@B11]\]          70.8 ± 10.2           71.2 ± 11.1        70.6         52.8                      100    100               NR
  Elbadawi et al, 2017\[[@B12]\]          71.3 ± 9              70.6 ± 8.7         78.5         76.1                      100    100               NR
  Friedman et al, 2018\[[@B14]\]          75 ± 5.9              76.4 ± 6.4         14.5         12.7                      50.5   43.4              Any technique
  Yao et al, 2018\[[@B13]\]               68.2 ± 10.6           65.8 ± 11.3        88.6         90.4                      75.4   31.4              

Clinical outcomes
-----------------

We evaluated the following clinical outcomes during follow-up in each report: (1) embolic events; (2) stroke; (3) all-cause mortality; (4) AF; (5) postoperative complications; and (6) reoperation for bleeding. We further performed stratified meta-analysis to evaluate the potential source of heterogeneity across the included studies. Stratification factors are inclusion of only propensity matched studies and studies with AF predominant cohort (\> 50% of study population having AF). The ischemic events attributed to embolic causes in the included studies were included in the embolic events. Complications included in the analysis are appendage tears, myocardial infarction, major bleeding, septicemia, pacemaker implants, renal failure, pericardial effusion, cardiac tamponade, and stroke.

Statistical analysis
--------------------

The meta-analysis was done using Review Manager (RevMan), Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014. Due to methodological and clinical heterogeneity between the included studies, a random-effects model estimating the odds ratio (OR) and the estimated 95% confidence interval (CI) of the above-mentioned outcomes were used. The OR estimate of each study was calculated by the random-effects model obtained by the DerSimonian-Lariad method\[[@B18]\].

Heterogeneity was assessed using Higgins' and Thompson's I2 statistic, with I2 values of \> 50% was considered significant. Publication bias was visually estimated by funnel plots. A 2-tailed *P* \< 0.05 was considered statistically significant for all analyses.

RESULTS
=======

Search results
--------------

A total of 1328 reports were retrieved during the initial search (Supplementary figure 1). 1049 reports were selected after removing 279 duplicates. 387 reports were screened and 354 were excluded. 33 reports were assessed for eligibility. Finally, after excluding 21 reports (no comparison groups-14, others-7) 12 studies were included. Among these 12 studies, three were randomized controlled trials (RCTs) and nine were observational studies. Among these nine observational studies, four were propensity matching studies\[[@B5],[@B6],[@B10],[@B13]\]. one was case matching study\[[@B12]\]. The inter-reviewer agreement on study eligibility was 100%.

Study characteristics
---------------------

The characteristics of the included studies are presented in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. Out of 40107 patients included, 13535 patients received s-LAAO during cardiac surgery while the remaining 26572 patients did not receive s-LAAO. The mean (SD) age of the study population ranged from 50.7 (12.4) years to 77.4 (6.8) years. The primary cardiac operation varied widely. The surgical procedures were primarily valve surgery in the studies by Garcia-Fernandez, Nagpal, Lee and Elbadawi\[[@B3],[@B5],[@B8],[@B12]\], while they were primarily coronary artery bypass grafting (CABG) in the studies by Healey, and Elbadawi\[[@B7],[@B11]\]. Remaining studies included a combination of valve surgery and CABG. Lee et al\[[@B5]\] also performed ablation of AF together with mitral valve surgery. The prevalence of AF varied in the study cohorts. The s-LAAO techniques varied; the methods variously included double suturing, exclusion, amputation, resection and stapling (Table [2](#T2){ref-type="table"}). The follow-up period ranged from in-hospital only to 109.2 mo.

Clinical outcomes
-----------------

s-LAAO was associated with lower risk of embolic events (OR: 0.63, 95%CI: 0.53-0.76; *P* \< 0.001) and a lower risk of stroke (OR: 0.68, 95%CI: 0.57-0.82; *P* \< 0.0001) (Figure [1A](#F1){ref-type="fig"} and 1B). There was no significant difference in all-cause mortality between the two groups (OR: 0.83, 95%CI: 0.51-1.36; *P* = 0.46) (Figure [1C](#F1){ref-type="fig"}). There was no significant difference in the incidence of follow-up AF between the two groups (OR: 1.41, 95%CI: 0.79-2.52, *P* = 0.24) (Figure [1D](#F1){ref-type="fig"}).

![Forest plots for study outcomes. A: Embolic events; B: Stroke; C: All-cause mortality; D: Atrial fibrillation; E: Postoperative complications; F: Reoperation for bleeding.](WJC-10-242-g001){#F1}

With regard to postoperative complications, there was no significant difference between the groups (OR: 1.44, 95%CI: 0.91-2.25; *P* = 0.12) (Figure [1F](#F1){ref-type="fig"}). Similarly, there was no significant difference in the incidence of reoperation for bleeding between the two groups (OR: 0.98, 95%CI: 0.57-1.69; *P* = 0.94) (Figure [1G](#F1){ref-type="fig"}).

Test of heterogeneity and publication bias
------------------------------------------

Test of heterogeneity was not significant for follow-up embolic events (*P* heterogeneity = 0.60, I2 = 0%) and stroke (*P* = 0.84, I2 = 0%), while it was significant for all-cause mortality (*P* \< 0.001, I2 = 92%), AF (*P* \< 0.001, I2 = 95%), postoperative complications (*P* = 0.004, I2 = 66%) and reoperation for bleeding (*P* = 0.20, I2 = 36%).

Subgroup analysis
-----------------

In subgroup analysis including only propensity matched studies, s-LAAO group had a trend towards lower risk of stroke (OR: 0.78, 95%CI: 0.60-1.00; *P* = 0.05), Supplementary Figure 2A. Test of heterogeneity was not significant (*P* = 0.63, I2 = 0%). There was no significant difference in the incidence of all-cause mortality (OR: 1.10, 95%CI: 0.34-3.60; *P* = 0.87), Supplementary Figure 2B. In subgroup analysis including only AF predominant studies (\> 50%), s-LAAO was associated with lower risk of stroke (OR: 0.60, 95%CI: 0.46-0.78; *P* = 0.0002) (Supplementary Figure 3A). There was no significant difference in all-cause mortality (OR: 0.87, 95%CI: 0.11-7.12; *P* = 0.89) (Supplementary Figure 3B). Test of heterogeneity was not significant for stroke (*P* = 0.86, I2 = 0%) while it was significant for all-cause mortality (*P* \< 0.001, I2 = 94%).

Funnel plot for visual inspection of publication bias is shown in Supplementary Figure 4.

DISCUSSION
==========

The main findings of our meta-analysis of patients undergoing s-LAAO during concomitant cardiac surgery are the following: (1) s-LAAO was associated with lower rates of embolic events and stroke; and (2) there was no significant difference in the incidence of all-cause mortality, postoperative complications or reoperations for bleeding between the two groups. The reduced risk of embolic events and stroke with s-LAAO was retained in the subgroup analysis including only studies with AF predominant population (Table [3](#T3){ref-type="table"}).

###### 

Complications reported in the individual studies

  **Study**                         **Total complications**      **Type of complications**                                                                                 
  --------------------------------- ---------------------------- --------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Healey et al, 2005\[[@B7]\]       8 (52) *vs* 1 (4)            8- intraoperative LAA tears                                                                               1- LAA tear
  Nagpal et al, 2009\[[@B8]\]       14 (63.6) *vs* 11 (52.3)     1- septicemia 1- myocardial infarction 2- RBC transfusion 8- temporary pacemaker 2- permanent pacemaker   1- RBC transfusion 7- temporary pacemaker 3- permanent pacemaker
  Whitlock et al, 2013\[[@B9]\]     1 (3.8) *vs* 2 (25)          1- major bleeding                                                                                         2- major bleeding
  Zapolonski et al, 2013\[[@B4]\]   3 (0.3) *vs* 5 (0.6)         3- myocardial infarction                                                                                  5- myocardial infarction
  Lee et al, 2014\[[@B5]\]          22 (18.4) *vs* 22 (18.4)     9- requirement of dialysis 4- permanent pacemaker insertion 1- wound revision 8- pericardial effusion     1- low cardiac output syndrome 10- dialysis 2- permanent pacemaker insertion 1- mediastinitis 2- wound revision 6- pericardial effusion
  Melduni et al, 2017\[[@B10]\]     32 (6.9) *vs* 32 (6.9)       14- pneumonia 18- acute renal failure                                                                     14- pneumonia 18- acute renal failure
  Elbadawi et al, 2017\[[@B11]\]    17 (3.1) *vs* 9 (1.6)        17- pericardial effusion                                                                                  7- pericardial effusion 2- hemorrhage
  Elbadawi et al, 2017\[[@B12]\]    1030 (40.8) *vs* 2903 (23)   16- cardiac tamponade 68- pericardial effusion 917- hemorrhage 29- postoperative shock                    19- cardiac tamponade 151- pericardial effusion 2687- hemorrhage 46- postoperative shock

RBC: Red blood cell; LAA: Left atrial appendage.

The estimated global prevalence of AF is on the rise due to a demographic shift with more prevalent ageing population carrying a higher burden of comorbidities\[[@B19]\]. About 25% of the strokes in the United States are related to AF and about 90% of the strokes in non-valvular AF are caused by thrombi originating in LAA\[[@B20]\]. Anticoagulants, both warfarin and direct acting oral anticoagulants (DOACs) reduce the incidence of stroke by more than 60%\[[@B21],[@B22]\] but they are associated with increasing risk of bleeding, and significant drug-drug interactions\[[@B16]\]. The benefits of anticoagulants are also limited by other issues including underutilization, poor compliance and cost\[[@B16]\].

The higher risk of stroke in the ageing population with AF has led to the increased adoption of LAA occlusion in clinical practice\[[@B23]\]. The two largest RCTs - PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) and PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) showed percutaneous LAAO being non-inferior to warfarin with respect to stroke rates and embolic events\[[@B24],[@B25]\]. Following the success with percutaneous LAAO, there has been a resurgence of interest in s-LAAO within the surgical community, especially with increase in the aging population and rising prevalence of AF\[[@B6],[@B10],[@B14]\].

Our findings show that s-LAAO was associated with lower risk of follow-up embolic events and stroke. The association of lower risk of stroke was more prominent in subgroup with AF predominant population. S-LAAO theoretically prevents formation of thrombus in LAA. However, successful s-LAAO is largely influenced by LAA morphology, occlusion technique and also operator skill. A previous study showed that a complete LAA occlusion was achieved in only 40%-50% of the patient population\[[@B10],[@B26]\]. The techniques of s-LAAO varied widely amongst the included studies as summarized in Table [2](#T2){ref-type="table"}. The excision technique to exclude LAA has been shown to have a higher success rate than the other modalities of s-LAAO\[[@B24]\]. Currently, concomitant LAA closure is given a Class IIb (level of evidence B) by the European Society of Cardiology (ESC)/European Society for Cardio-Thoracic Surgery (EACTS) guidelines and a Class IIb (level of evidence C) by the 2017 Society of Thoracic Surgeons guidelines (STS)\[[@B16]\]. Therefore, there is a wide practice level variation in the utilization of s-LAAO during cardiac surgery. The number of studies with a particular technique is inadequate to perform individual technique based meta-analysis so we combined all different techniques of s-LAAO in our meta-analysis. It should be noted that none of the other studies except the study from Friedman et al\[[@B14]\] reported long-term benefits. However, Friedman et al\[[@B14]\] showed a remarkable reduction in postoperative embolism at follow up. Further studies with long-term follow up of embolic events are essential. Our results are similar to a previous meta-analysis comparing s-LAAO vs no occlusion\[[@B27],[@B28]\]. However, we included additional studies by Friedman et al\[[@B14]\], Elbadawi et al\[[@B11]\] and Yao et al\[[@B13]\] yielding a larger sample size. In addition, we performed a subgroup analysis of the included studies to identify the patient population that is most likely to benefit from this procedure.

In the current study, we found no significant difference in the risk of postoperative complications and reoperation for bleeding. s-LAAO is associated with inherent risk of procedural complications including LAA tears as observed in the study by Healey et al\[[@B7]\] and so learning curve plays an essential role in success of the procedure. Hypothetically, avoidance of aggressive anticoagulation after s-LAAO might have contributed to some of the benefits observed with s-LAAO. However, only few studies reported the long-term details of anticoagulation. Lee et al\[[@B5]\] reported no difference in the utilization of anticoagulation between the two groups (62.2% *vs* 55.4%). In the study by Friedman et al\[[@B14]\], anticoagulation was prescribed to 68.9% of the patients in the s-LAAO group compared to only 60.3% in the group without s-LAAO. In contrast to percutaneous LAAO, evidence regarding the utilization of anticoagulation after s-LAAO is not clear. The 2016 ESC/EACTS guidelines still recommend therapeutic anti-coagulation in all patients despite s-LAAO (Class I, level of evidence B)\[[@B15]\]. With lack of long term data, there is need for prospective trials to address this issue. The ongoing LAAOS-III (left atrial appendage occlusion study III) and the ATLAS (AtriClip^®^ Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures) trials should be able to provide further insights into the benefits of s-LAAO.

LIMITATIONS
===========

Our study should be viewed in the context of following limitations. First, due to the small number of studies with small sample sizes, except the study by Friedman et al\[[@B14]\], the results might be underpowered to detect the true clinical benefits of certain clinical outcomes. Second, there was a wide variation of surgical techniques of LAAO, so we were not able to address the effect of individual techniques. Third, only Friedman et al\[[@B14]\] reported long-term embolic events, whereas the other studies did not report long term outcomes. The study by Friedman et al\[[@B14]\] reported readmissions for embolic events, so some of the events which did not require hospitalization were not included. The effect of anticoagulation on postoperative outcomes remains unclear due to inadequate reporting in the included studies. Fourth, it is unclear if s-LAAO increases the duration of the surgical procedure as it was only reported in two studies. Fifth, the burden of AF varied among the included studies, thus carrying risk of a selection bias. Finally, publication bias is an inherent limitation of any meta-analysis.

CONCLUSION
==========

In conclusion, our results support the safety of s-LAAO and favor its continued use in conjunction with concomitant cardiac surgery, especially in patients with AF. Randomized controlled trials are essential to evaluate the long-term benefits of s-LAAO.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The left atrial appendage (LAA) is a common site for intracardiac thrombus formation in patients with atrial fibrillation (AF). Surgical left atrial appendage occlusion (s-LAAO) during concomitant cardiac surgery has been evaluated as an effective treatment approach to reduce the risk of stroke and embolic events.

Research motivation
-------------------

Percutaneous LAAO has been shown to be non-inferior compared with warfarin in reducing the risk of stroke and embolic events in two large randomized controlled trials, PROTECT-AF and PREVAIL. However, data regarding s-LAAO is conflicting and contrasting. So, we performed a systematic review and meta-analysis of all the studies published to date to evaluate if concomitant s-LAAO during cardiac surgery is safe and effective.

Research objectives
-------------------

The purpose of this study is to evaluate the safety and efficacy of concomitant s-LAAO during cardiac surgery.

Research methods
----------------

We searched five databases for studies comparing concomitant s-LAAO with no occlusion during cardiac surgery. We obtained a total of 12 studies for inclusion and performed a meta-analysis. The outcomes of interest were embolic events, stroke, all-cause mortality, AF, postoperative complications and reoperation for bleeding.

Research results
----------------

Concomitant s-LAAO during cardiac surgery was associated with lower risk of embolic events and stroke. This was evident in the AF predominant strata as well. There was no significant difference in the risk of all-cause mortality, AF, postoperative complications and reoperation for bleeding.

Research conclusions
--------------------

Our meta-analysis including all the studies published to date comparing concomitant s-LAAO against no occlusion during cardiac surgery supports the use of concomitant s-LAAO during cardiac surgeries. It was associated with lower risk of stroke and embolic events.

Research perspectives
---------------------

From this meta-analysis, it could be seen that concomitant s-LAAO during cardiac surgeries was associated with lower risk of stroke and embolic events compared with no occlusion. This association was prominent amongst the AF predominant strata as well. These beneficial effects could be seen due to the occlusion of LAA which is the source of 90% thrombi in non-valvular AF. Future randomized trials are needed to evaluate the long term benefits of s-LAAO.
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